2018
New‐onset refractory status epilepticus (NORSE) and febrile infection–related epilepsy syndrome (FIRES): State of the art and perspectives
Gaspard N, Hirsch LJ, Sculier C, Loddenkemper T, van Baalen A, Lancrenon J, Emmery M, Specchio N, Farias‐Moeller R, Wong N, Nabbout R. New‐onset refractory status epilepticus (NORSE) and febrile infection–related epilepsy syndrome (FIRES): State of the art and perspectives. Epilepsia 2018, 59: 745-752. PMID: 29476535, DOI: 10.1111/epi.14022.Peer-Reviewed Original ResearchConceptsNew-onset refractory status epilepticusFebrile infection-related epilepsy syndromeRefractory status epilepticusStatus epilepticusCytokine-mediated mechanismOptimal treatment optionsAdult-onset formStrong scientific evidenceStandardized consensus definitionsMulticenter registryPrompt treatmentKetogenic dietUncontrolled trialsEpilepsy syndromesImmune therapyTreatment optionsEarly recognitionClinical careConsensus definitionClinical situationsPatient careEpilepticusStandardized definitionsElectroencephalography featuresScientific evidence
2013
Unified EEG terminology and criteria for nonconvulsive status epilepticus
Beniczky S, Hirsch LJ, Kaplan PW, Pressler R, Bauer G, Aurlien H, Brøgger JC, Trinka E. Unified EEG terminology and criteria for nonconvulsive status epilepticus. Epilepsia 2013, 54: 28-29. PMID: 24001066, DOI: 10.1111/epi.12270.Peer-Reviewed Original Research
2011
The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy
Arif H, Svoronos A, Resor SR, Buchsbaum R, Hirsch LJ. The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy. Epilepsia 2011, 52: 1905-1913. PMID: 21838791, DOI: 10.1111/j.1528-1167.2011.03217.x.Peer-Reviewed Original ResearchConceptsLTG clearanceOlder adultsYoung adultsOlder patientsSeizure freedomYounger patientsAdverse effectsOne-year retentionEfficacy of lamotrigineIntolerable side effectsHigher serum levelsSpecific adverse effectsSignificant adverse effectsLamotrigine clearanceEffect of ageApparent clearanceSerum levelsLTG levelsOldest tertileAdult outpatientsSide effectsPatientsLamotrigineEnzyme inducersIntolerability
2007
Effect of Age and Comedication on Levetiracetam Pharmacokinetics and Tolerability
Hirsch LJ, Arif H, Buchsbaum R, Weintraub D, Lee J, Chang JT, Resor SR, Bazil CW. Effect of Age and Comedication on Levetiracetam Pharmacokinetics and Tolerability. Epilepsia 2007, 48: 1351-1359. PMID: 17573925, DOI: 10.1111/j.1528-1167.2007.01043.x.Peer-Reviewed Original ResearchConceptsTolerability of levetiracetamLEV clearanceOlder adultsYoung adultsAdverse effectsEnzyme-inducing antiepileptic drugsOlder groupSame serum levelsCommon adverse effectsSubgroup of patientsGroup of patientsSpecific adverse effectsBehavioral side effectsOne-year retentionLevetiracetam pharmacokineticsEffect of ageOlder patientsYounger patientsApparent clearanceSerum levelsAntiepileptic drugsLEV useAdult outpatientsLow doseLevetiracetam
2006
Nonconvulsive Status Epilepticus in Children: Clinical and EEG Characteristics
Tay SK, Hirsch LJ, Leary L, Jette N, Wittman J, Akman CI. Nonconvulsive Status Epilepticus in Children: Clinical and EEG Characteristics. Epilepsia 2006, 47: 1504-1509. PMID: 16981867, DOI: 10.1111/j.1528-1167.2006.00623.x.Peer-Reviewed Original ResearchConceptsNonconvulsive status epilepticusConvulsive status epilepticusPeriodic lateralized epileptiform dischargesPediatric patientsStatus epilepticusEpileptiform dischargesDiagnosis of NCSEAcute hypoxic-ischemic injuryAntiepileptic drug regimenAcute medical illnessHypoxic-ischemic injuryComprehensive Epilepsy CenterContinuous electroencephalographic monitoringPeriodic epileptiform dischargesHeterogeneous clinical conditionYears of ageFrequent etiologyNeurological outcomeChart reviewDrug regimenAcute infectionAcute settingConvulsive seizuresPrompt recognitionRefractory epilepsyPredictors of Lamotrigine‐associated Rash
Hirsch LJ, Weintraub DB, Buchsbaum R, Spencer HT, Straka T, Hager M, Resor SR. Predictors of Lamotrigine‐associated Rash. Epilepsia 2006, 47: 318-322. PMID: 16499755, DOI: 10.1111/j.1528-1167.2006.00423.x.Peer-Reviewed Original ResearchConceptsAntiepileptic drugsRisk factorsColumbia Comprehensive Epilepsy CenterDrug-related rashStevens-Johnson syndromeToxic epidermal necrolysisComprehensive Epilepsy CenterHistory of rashGreatest risk factorEpidermal necrolysisSevere rashEpilepsy centersMedical historyRemote historyRetrospective analysisRashMedication variablesMultivariate analysisPotential predictorsPatientsStrongest predictorPredictorsLTGTitration rateChildren
2003
Absence Epilepsy with Onset before Age Three Years: Could this Be Glut‐1 Deficiency Syndrome (De Vivo Syndrome)?
Hirsch LJ. Absence Epilepsy with Onset before Age Three Years: Could this Be Glut‐1 Deficiency Syndrome (De Vivo Syndrome)? Epilepsia 2003, 45: 92-93. PMID: 14692915, DOI: 10.1111/j.0013-9580.2004.41503.x.Peer-Reviewed Original Research